News

Genetic Marker HLA-B27 Correlates With Ankylosing Spondylitis Onset but Not Disease Burden, Study Shows

The presence of a specific genetic marker called HLA-B27 in Caucasian ankylosing spondylitis patients is related to earlier disease onset and higher disease prevalence among family members, a study has found. However, according to the research, being HLAB27-positive is not related to a higher burden of disease or uveitis (inflammation of the eye).

Anti-Rheumatic or Anti-Tumor Necrosis Therapy Does Not Contribute to Increased Infection Risk, Study Shows

Patients with ankylosing spondylitis treated with anti-rheumatic drugs or anti-tumor necrosis therapy are not more likely to develop infections compared to non-users, a study shows. The study, “Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis,” was published in the…

Cosentyx Safe, Effective Through 5 Years of Treatment, Novartis Announces

Five-year treatment with Cosentyx (secukinumab) is safe and effective in easing signs and symptoms of ankylosing spondylitis (AS), according to results of a Phase 3 extension clinical trial. This new data are scheduled to be presented Oct. 23 at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual…